Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A high-quality and -throughput colloidal lithography by mechanical assembly and ice-based transfer.

Nanoscale·2025
Same author

OncoAID: an open access targeted anti-cancer drugs database.

Frontiers in pharmacology·2025
Same author

Tiny Clusters for Big Impact in T Cell Activation.

Nano letters·2025
Same author

HLA-E[pHLA-G] complex-specific monoclonal antibody enhancing NK activity in multiple myeloma.

Blood advances·2025
Same author

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.

Oncotarget·2025
Same author

Characterization of the xeno-GVHD response generated by advanced lung cancer patient peripheral blood mononuclear cells in NSG-SGM3 mice.

Translational lung cancer research·2025

Related Experiment Video

Updated: Jul 16, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

OptiRanker: a simulation and optimization framework for efficient in vivo validation of drug prioritization

Ohad Landau1, Kartheeswaran Thangathurai2,3, Shai Magidi4

  • 1Ben Gurion University of the Negev, Beer-Sheva, Israel. ohadlan@post.bgu.ac.il.

Scientific Reports
|July 14, 2026
PubMed
Summary

OptiRanker optimizes drug prioritization by simulating experiments to find the smallest effective cohort size. This computational framework reduces experimental scale while maintaining accurate drug ranking for personalized medicine.

Related Experiment Videos

Last Updated: Jul 16, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Area of Science:

  • Computational biology
  • Bioinformatics
  • Pharmacogenomics

Background:

  • Personalized medicine requires optimal drug selection based on individual patient profiles.
  • Drug prioritization algorithms using omics data are increasing, but lack rigorous in vivo validation.
  • Efficient frameworks are needed to determine minimal experimental cohort sizes for robust results.

Purpose of the Study:

  • To introduce OptiRanker, a statistical simulation framework for optimizing in vivo validation of drug prioritization algorithms.
  • To enable the determination of the smallest experimental cohort size that yields statistically robust outcomes.
  • To reduce the scale of experimental validation for computational drug discovery tools.

Main Methods:

  • OptiRanker perturbs algorithmic predictions with controlled noise to assess performance ranking preservation.
  • It uses weighted mean squared error (WMSE) and Spearman correlation against baseline rankings.
  • In silico validation involved 36 drug IC50s, 798 cell-line models, and 3 published algorithms.

Main Results:

  • Accurate predictor rankings were recovered across simulated conditions, substantially reducing experimental scale.
  • The full predictor ranking was achieved with as few as six individuals and one drug in silico.
  • OptiRanker demonstrated the ability to identify minimal cohorts for statistically robust results.

Conclusions:

  • OptiRanker provides a reproducible and exploratory approach to optimize in vivo validation trials.
  • It addresses a key bottleneck in translating computational models into clinical applications.
  • The framework facilitates the development of clinically actionable tools for personalized medicine by optimizing experimental design.